Onglyza, a medication used to treat type 2 diabetes, was first approved by the FDA in 2009. [1] Sanofi and Bristol-Myers Squibb originally held the patent for Onglyza, but it began to go off-patent in 2017 [2].

On June 1, 2023, the patents for Onglyza expired, marking the beginning of the period for generic versions of the medication to become available. [2] According to DrugPatentWatch.com, generic versions of Onglyza, including those from companies such as Mylan and Teva, were approved in the United States and are now available for consumers. [3]

Generic Onglyza is manufactured by companies such as Mylan Pharmaceuticals, Teva Pharmaceuticals, and others [4]. DrugPatentWatch.com provides a comprehensive list of generic manufacturers for Onglyza, which can be accessed on their website. [3]

However, it is worth noting that generic versions may not be exact replicas of the original medication, but they are designed to be bioequivalent, meaning they will have the same effect on the body. Patients who are currently taking Onglyza should consult their doctors before switching to a generic version.

Sources:

1. FDA.gov [https://www.fda.gov/news-events/press-announcements/ FDA-approves-saxagliptin-for-type-2-diabetes]
2. DrugPatentWatch.com [https://www.drugpatentwatch.com/drug/onglyza]
3. DrugPatentWatch.com [https://www.drugpatentwatch.com/drug/onglyza/generics]
4. Drugs.com [https://www.drugs.com/onglyza.html]